Chemical compound
Pharmaceutical compound
Enprofylline (3-propylxanthine) is a xanthine derivative used in the treatment of asthma, which acts as a bronchodilator. It acts primarily as a competitive nonselective phosphodiesterase inhibitor with relatively little activity as a nonselective adenosine receptor antagonist.[1][2]
References
- ^ Lunell E, Svedmyr N, Andersson KE, Persson CG (1982). “Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease”. European Journal of Clinical Pharmacology. 22 (5): 395–402. doi:10.1007/bf00542541. PMID 6288396. S2CID 3240010.
- ^ Laursen LC (December 1987). “Anti asthmatic effects and pharmacokinetics of enprofylline–a new xanthine derivate”. Danish Medical Bulletin. 34 (6): 289–97. PMID 3325233.
| PDE1 | |
|---|---|
| PDE2 | |
| PDE3 | |
| PDE4 |
|
| PDE5 | |
| PDE7 | |
| PDE9 | |
| PDE10 | |
| PDE11 | |
| Non-selective | |
| Unsorted | |
See also: Receptor/signaling modulators | |
| Receptor (ligands) |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (blockers) |
| ||||||||||
| Enzyme (inhibitors) |
| ||||||||||
| Others | |||||||||||
See also: Receptor/signaling modulators | |||||||||||